BioLineRx Ltd. (BLRX)
| Market Cap | 13.19M -18.2% |
| Revenue (ttm) | 1.40M -93.7% |
| Net Income | -7.90M |
| EPS | -0.00 |
| Shares Out | 2.61B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,002 |
| Open | 2.560 |
| Previous Close | 2.760 |
| Day's Range | 2.560 - 2.720 |
| 52-Week Range | 2.150 - 4.560 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About BLRX
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic... [Read more]
Financial Performance
In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.
Financial StatementsNews
BioLineRx prices 1.35M ADSs at $2.78 in registered direct offering
BioLineRx (BLRX) announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the company’s American Depositary Shares at a purchase price of…
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies i...
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and...
BioLineRx (BLRX) Reveals Promising Ovarian Cancer Treatment Data
BioLineRx (BLRX) Reveals Promising Ovarian Cancer Treatment Data
BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
BioLineRx (BLRX) announced new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft model of ovarian cancer. Today’s results represent a “comp...
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individual...
BioLineRx (BLRX) Q1 2026 Earnings Transcript
BioLineRx (BLRX) Q1 2026 Earnings Transcript
BLRX Achieves Key Milestones in Clinical Development and Revenue Growth
BLRX Achieves Key Milestones in Clinical Development and Revenue Growth
BioLineRx Earnings Call Transcript: Q1 2026
GLIX1 entered phase I/IIa trials for GBM, showing strong preclinical results and broad market potential. APHEXDA sales and royalties grew significantly, while R&D expenses rose due to pipeline expansion. Cash reserves are sufficient into 2027.
BioLineRx Earnings release: Q1 2026
BioLineRx released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
BioLineRx reports Q1 EPS 0c vs. (0c) last year
Reports Q1 revenue $0.5M vs.$0.3M last year. “Since our last quarterly update, we achieved a significant milestone for our company and for the GLIX1 development program with the dosing of…
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-...
BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026
BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and ...
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx (BLRX) Reports Promising Preclinical Results for GLIX1 in GBM Treatment
BioLineRx (BLRX) Reports Promising Preclinical Results for GLIX1 in GBM Treatment
BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM
BioLineRx (BLRX) and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging new preclinical data that further support the recentl...
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potentia...
BioLineRx (BLRX) Begins Phase 1/2a Study of GLIX1 for Glioblastoma Treatment
BioLineRx (BLRX) Begins Phase 1/2a Study of GLIX1 for Glioblastoma Treatment
BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1
BioLineRx (BLRX) and Hemispherian announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma and other
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Pha...
BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial
BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial
BioLineRx, Hemispherian initiate clinical trial of GLIX1
Hemispherian announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma and other high-grade gliomas. The study is being co...
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical t...